| Field | Specification |
|---|---|
| Target | |
| Alternative names | Runt-related transcription factor 2; Acute myeloid leukemia 3 protein; Core-binding factor subunit alpha-1; CBF-alpha-1; Oncogene AML-3; Osteoblast-specific transcription factor 2; OSF-2; Polyomavirus enhancer-binding protein 2 alpha A subunit; PEA2-alpha A; PEBP2-alpha A; SL3-3 enhancer factor 1 alpha A subunit; SL3/AKV core-binding factor alpha A subunit; RUNX2; AML3; CBFA1; OSF2; PEBP2A |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human RUNX2. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone HCO-18 is a rabbit monoclonal antibody that recognizes runt-related transcription factor 2 (gene RUNX2) in human, mouse and rat samples and is validated for ICC/IF, IHC and Western blot. The predicted molecular weight is 56.6 kDa, and the supplier reports an observed band at about 57 kDa.
RUNX2 is the master transcription factor for bone formation, required for osteoblast maturation and for both intramembranous and endochondral ossification. It drives genes such as osteocalcin, osteopontin and type I collagen, making it a standard marker in studies of skeletal development, osteogenic differentiation and bone disease.
| Target | Runt-related transcription factor 2 (gene RUNX2; UniProt Q13950, human) |
|---|---|
| Clone | HCO-18 |
| Host / Clonality / Isotype | Rabbit / Monoclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Liquid |
| Formulation | PBS (pH 7.4); 150 mM NaCl; 0.02% sodium azide; 50% glycerol; plus stabilizers |
| Calculated MW | 56.6 kDa |
| Observed MW | 57 kDa |
| Storage | Long term: −20 °C for up to 12 months. Frequent use: 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 1:500–1:2000 |
|---|---|
| Immunohistochemistry | 1:50–1:200 |
| Immunocytochemistry / Immunofluorescence | 1:50–1:200 |
Samples with a confirmed band (WB): human THP-1 cells, human U251 cells, human RT4 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 1:500 overnight at 4 °C, HRP-conjugated secondary antibody at 1:500, ECL detection.
Samples with confirmed staining (IHC): human colon tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): Saos-2 cells.
Immunogen
Synthetic peptide based on the sequence of human RUNX2.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places runt-related transcription factor 2 in the nucleus and cytoplasm. Tissue expression noted by UniProt (human): Specifically expressed in osteoblasts. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Xiaodong Hu et al. (2025) Virulence-Selective Trap–Capture–Kill Antibacterial Nanostructures With Immune–Metabolic Regulation for Treating Implant-Associated Infections. Advanced Science. 10.1002/advs.202511045
Jiaqi Zhong et al. (2024) Bisphosphonates activated keratin assembled nanoparticle targeting bone fracture for enhanced immunomodulatory and osteoinductivity. Chemical Engineering Journal. 10.1016/j.cej.2024.151265
Weiqiang Hu et al. (2025) Zeolitic imidazolate frameworks exert bioenergetic modulation via the cAMP/PKA/CREB signaling pathway to accelerate periodontal regeneration. Chemical Engineering Journal. 10.1016/j.cej.2025.171251
Nan Wang et al. (2025) Immunomodulatory mesoporous bioactive glass/interleukin-4 nanocomplex promotes bone regeneration. International Journal of Biological Macromolecules. 10.1016/j.ijbiomac.2025.149869
Peng Pan et al. (2024) Barrier Membrane with Janus Function and Structure for Guided Bone Regeneration. ACS Applied Materials & Interfaces. 10.1021/acsami.4c08737
Hongjuan Cao et al. (2026) Injectable, regenerative and anti-infective PEGylated polyglycerol sebacate-modified calcium phosphate cements triggered by berberine and rhBMP-2 for oral bone defect repair. Dental Materials. 10.1016/j.dental.2026.01.012
Liu Yijuan et al. (2024) Self-assembled peptide hydrogel loaded with functional peptide dentonin accelerates vascularized bone tissue regeneration in critical-size bone defects. Regenerative Biomaterials. 10.1093/rb/rbae106
Wenhao Cheng et al. (2026) Black Phosphorus Nanosheets for Enhanced Osteogenic Differentiation of Dental Follicle Stem Cells. ACS Applied Nano Materials. 10.1021/acsanm.6c00876
Chao Shan et al. (2024) Network pharmacological study and in vitro studies validation-Molecular dynamics simulation of Cistanche deserticola in promoting periodontitis and bone remodeling. International Immunopharmacology. 10.1016/j.intimp.2024.112299
Jia Yi Chen et al. (2025) Mechanical Stretch Prevents Senescence-Associated Osteogenic Impairment in Mesenchymal Stem Cells via CXCR4/PI3K/AKT Signaling. FASEB Journal. 10.1096/fj.202500239R
